Cangrelor Following Ticagrelor Loading vs Ticagrelor Loading Alone in STEMI
Status:
Completed
Trial end date:
2017-12-26
Target enrollment:
Participant gender:
Summary
Platelets and thrombus formation play a key role in the pathogenesis of acute coronary artery
occlusion and subsequent myocardial infarction. Apart from mechanically opening the occluded
artery with angioplasty, adjunctive antiplatelet treatment is of utmost importance. However,
orally administered antiplatelet agents exhibit a delay in their onset of action in the
setting of acute myocardial infarction and angioplasty is mostly performed without adequate
platelet inhibition. Cangrelor is an intravenous antiplatelet agent which can provide almost
immediate strong platelet inhibition. The investigators aim to compare a strategy of
cangrelor administered on top of ticagrelor-an oral antiplatelet agent- vs ticagrelor alone,
on their efficacy to inhibit platelet function in the early hours of an acute myocardial
infarction.
Phase:
Phase 4
Details
Lead Sponsor:
Attikon Hospital
Collaborators:
AHEPA University Hospital University Hospital, Alexandroupolis